12 月龄时，1 剂、2 剂或 3 剂婴幼儿期 7 价肺炎球菌结合疫苗后，23 价肺炎球菌多糖疫苗的安全性和免疫原性。
Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy.
机构信息
Centre for International Child Health, Department of Paediatrics, University of Melbourne, Royal Children's Hospital, Melbourne, Australia.
出版信息
Vaccine. 2010 Apr 19;28(18):3086-94. doi: 10.1016/j.vaccine.2010.02.065. Epub 2010 Mar 1.
Abstract
Fijian infants aged 6 weeks were stratified by ethnicity and randomized to receive 0, 1, 2, or 3 PCV-7 doses with or without the 23-valent pneumococcal polysaccharide vaccine (PPV-23) at 12 months. Strong booster effects for all 7 PCV-7 serotypes were elicited, and for 4/7 serotypes these responses were highest in the single PCV-7 group. There were fourfold rises in GMC for all non-PCV-7 serotypes. By 17 months the PPV-23 group still had significantly higher GMC (each p<0.001) for all serotypes. The PPV-23 was well tolerated and induced excellent responses for all serotypes which were greatest in the single PCV-7 group.
摘要
6 周龄斐济婴儿按种族分层，随机分为接受 0、1、2 或 3 剂 PCV-7 加或不加 12 个月时的 23 价肺炎球菌多糖疫苗（PPV-23）组。所有 7 种 PCV-7 血清型均引起强烈的增强效应，4/7 种血清型在单剂 PCV-7 组的反应最高。所有非 PCV-7 血清型的 GMC 均有 4 倍升高。到 17 个月时，PPV-23 组所有血清型的 GMC 仍显著较高（p<0.001）。PPV-23 耐受性良好，引起所有血清型的良好反应，在单剂 PCV-7 组最大。
相似文献
1
Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy.
Vaccine. 2010 Apr 19;28(18):3086-94. doi: 10.1016/j.vaccine.2010.02.065. Epub 2010 Mar 1.
2
Serotype-specific avidity is achieved following a single dose of the 7-valent pneumococcal conjugate vaccine, and is enhanced by 23-valent pneumococcal polysaccharide booster at 12 months.
Vaccine. 2011 Jun 15;29(27):4499-506. doi: 10.1016/j.vaccine.2011.04.038. Epub 2011 May 1.
3
The Antibody Response Following a Booster With Either a 10- or 13-valent Pneumococcal Conjugate Vaccine in Toddlers Primed With a 13-valent Pneumococcal Conjugate Vaccine in Early Infancy.
Pediatr Infect Dis J. 2016 Jul;35(7):787-93. doi: 10.1097/INF.0000000000001180.
4
Immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine as a booster dose in 12- to 18-month-old children primed with 3 doses of 7-valent pneumococcal conjugate vaccine.
Hum Vaccin Immunother. 2014;10(7):1859-65. doi: 10.4161/hv.28642.
5
Opsonophagocytic activity following a reduced dose 7-valent pneumococcal conjugate vaccine infant primary series and 23-valent pneumococcal polysaccharide vaccine at 12 months of age.
Vaccine. 2011 Jan 10;29(3):535-44. doi: 10.1016/j.vaccine.2010.10.046. Epub 2010 Oct 31.
6
Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants with human immunodeficiency virus type 1 infection.
Pediatrics. 2003 Jul;112(1 Pt 1):66-73. doi: 10.1542/peds.112.1.66.
7
Hyporesponsiveness to re-challenge dose following pneumococcal polysaccharide vaccine at 12 months of age, a randomized controlled trial.
Vaccine. 2010 Apr 26;28(19):3341-9. doi: 10.1016/j.vaccine.2010.02.087. Epub 2010 Mar 4.
8
Immunogenicity of a single-dose compared with a two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine in South African children: an open-label, randomised, non-inferiority trial.
Lancet Infect Dis. 2020 Dec;20(12):1426-1436. doi: 10.1016/S1473-3099(20)30289-9. Epub 2020 Aug 25.
9
Immunogenicity and safety of a 14-valent pneumococcal polysaccharide conjugate vaccine (PNEUBEVAX 14™) administered to 6-8 weeks old healthy Indian Infants: A single blind, randomized, active-controlled, Phase-III study.
Vaccine. 2024 May 10;42(13):3157-3165. doi: 10.1016/j.vaccine.2024.03.056. Epub 2024 Apr 17.
10
Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers.
Clin Vaccine Immunol. 2010 Jun;17(6):1017-26. doi: 10.1128/CVI.00062-10. Epub 2010 Apr 28.
引用本文的文献
1
Pneumococcal conjugate vaccination schedules in infants-acquisition, immunogenicity, and pneumococcal conjugate and yellow fever vaccine co-administration study: statistical analysis plan.
Trials. 2024 Mar 26;25(1):216. doi: 10.1186/s13063-024-08036-6.
2
Simplified 0+1 and 1+1 pneumococcal vaccine schedules in Ho Chi Minh City, Vietnam: protocol for a randomised controlled trial.
BMJ Open. 2021 Nov 29;11(11):e056505. doi: 10.1136/bmjopen-2021-056505.
3
Australia's Role in Pneumococcal and Human Papillomavirus Vaccine Evaluation in Asia-Pacific.
Vaccines (Basel). 2021 Aug 18;9(8):921. doi: 10.3390/vaccines9080921.
4
Vaccination for the control of childhood bacterial pneumonia - type b and pneumococcal vaccines.
Pneumonia (Nathan). 2016 Jul 2;2:2-15. doi: 10.15172/pneu.2013.2/229. eCollection 2013.
5
The association between pneumococcal vaccination, ethnicity, and the nasopharyngeal microbiota of children in Fiji.
Microbiome. 2019 Jul 16;7(1):106. doi: 10.1186/s40168-019-0716-4.
6
Evaluation of different infant vaccination schedules incorporating pneumococcal vaccination (The Vietnam Pneumococcal Project): protocol of a randomised controlled trial.
BMJ Open. 2018 Jun 8;8(6):e019795. doi: 10.1136/bmjopen-2017-019795.
7
No long-term evidence of hyporesponsiveness after use of pneumococcal conjugate vaccine in children previously immunized with pneumococcal polysaccharide vaccine.
J Allergy Clin Immunol. 2016 Jun;137(6):1772-1779.e11. doi: 10.1016/j.jaci.2015.12.1303. Epub 2016 Jan 26.
8
Immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine as a booster dose in 12- to 18-month-old children primed with 3 doses of 7-valent pneumococcal conjugate vaccine.
Hum Vaccin Immunother. 2014;10(7):1859-65. doi: 10.4161/hv.28642.
9
Evaluation of the induction of immune memory following infant immunisation with serogroup C Neisseria meningitidis conjugate vaccines--exploratory analyses within a randomised controlled trial.
PLoS One. 2014 Jul 14;9(7):e101672. doi: 10.1371/journal.pone.0101672. eCollection 2014.
10
Maternal Supplementation with LGG Reduces Vaccine-Specific Immune Responses in Infants at High-Risk of Developing Allergic Disease.
Front Immunol. 2013 Nov 26;4:381. doi: 10.3389/fimmu.2013.00381. eCollection 2013.
本文引用的文献
1
Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates.
Lancet. 2009 Sep 12;374(9693):893-902. doi: 10.1016/S0140-6736(09)61204-6.
2
Immunogenicity following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine.
Vaccine. 2009 Sep 18;27(41):5685-91. doi: 10.1016/j.vaccine.2009.06.098. Epub 2009 Jul 17.
3
Safety and immunogenicity of sequential pneumococcal immunization in preschool asthmatics.
Vaccine. 2009 Aug 20;27(38):5259-64. doi: 10.1016/j.vaccine.2009.06.054. Epub 2009 Jul 2.
4
Indirect effect of 7-valent pneumococcal conjugate vaccine on pneumococcal colonization among unvaccinated household members.
Clin Infect Dis. 2008 Oct 15;47(8):989-96. doi: 10.1086/591966.
5
Reconsideration of the use of meningococcal polysaccharide vaccine.
Pediatr Infect Dis J. 2007 Aug;26(8):716-22. doi: 10.1097/INF.0b013e3180cc2c25.
6
Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue?
Lancet Infect Dis. 2007 Sep;7(9):597-606. doi: 10.1016/S1473-3099(07)70210-4.
7
Emergence of 19A as virulent and multidrug resistant Pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine.
Pediatr Infect Dis J. 2007 Jun;26(6):468-72. doi: 10.1097/INF.0b013e31803df9ca.
8
Discovery of a new capsular serotype (6C) within serogroup 6 of Streptococcus pneumoniae.
J Clin Microbiol. 2007 Apr;45(4):1225-33. doi: 10.1128/JCM.02199-06. Epub 2007 Jan 31.
9
Functional antibodies elicited by two heptavalent pneumococcal conjugate vaccines in the Finnish Otitis Media Vaccine Trial.
Infect Immun. 2007 Apr;75(4):1794-800. doi: 10.1128/IAI.01673-06. Epub 2007 Jan 29.
10
Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease.
J Infect Dis. 2006 Jun 1;193(11):1487-94. doi: 10.1086/503805. Epub 2006 Apr 27.
Zotero 插件